DK2756305T3 - Fremgangsmåde til bestemmelse af glycosyleringen af et antistof - Google Patents
Fremgangsmåde til bestemmelse af glycosyleringen af et antistof Download PDFInfo
- Publication number
- DK2756305T3 DK2756305T3 DK12767069.3T DK12767069T DK2756305T3 DK 2756305 T3 DK2756305 T3 DK 2756305T3 DK 12767069 T DK12767069 T DK 12767069T DK 2756305 T3 DK2756305 T3 DK 2756305T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- receptor
- competing
- cells
- glycosylation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
1. in vitro fremgangsmåde til bestemmelse af bindingen af et konkurrerende antistof med en Fc-receptor eksprimeret i cellemembraner eller intakte celler foreliggende i et målemedie, ved konkurrering med et referenceantistof, omfattende følgende trin: (i) direkte mærkning af den nævnte Fc-receptor med det første medlem af et par FRET partnere, ellers introduktion, i mediet, af cellemembraner eller intakte celler, hvis Fc-receptorer blev mærkede på forhånd direkte med det første medlem af et par af FRET partnere; (ii) tilføjelse af det konkurrerende antistof til målemediet; (iii) tilføjelse af et referenceantistof, som er markeret direkte med det andet medlem af parret af FRET partnere, til målemediet; (iv) måling af FRET signalet, idet en reduktion af signalet målt under tilstedeværelse af det konkurrerende antistof i forhold til det, som er målt under dettes fravær, er repræsentativt for bindingen af dette antistof til Fc-receptoren; kendetegnet ved, at Fc-receptoren er mærket direkte via et suicid-enzym, dvs. at det er eksprimeret i form af et fusionsprotein omfattende Fc-receptoren og suicid-enzymet, og at markeringen udføres ved tilføjelse af substratet af enzymet, konjugeret med en af FRET partnerne, til målemediet.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at trin (ii) reproduceres med forskellige mængder af konkurrerende antistof, idet mængden af referenceantistof tilføjet i trin (iii) er fast, og at det omfatter et yderligere trin (v) ved bestemmelse af EC50 for det konkurrerende antistof og med sammenligning med EC50 for referenceantistoffet.
3. Fremgangsmåde ifølge krav 1 og 2, kendetegnet ved, at referenceantistoffet og det konkurrerende antistof afvigeer især ved, at sidstnævnte blev fremstillet ved en fremgangsmåde, eller er blevet underkastet en behandling, som sigter mod at ændre niveauet for glycosylering af dettes Fc-fragment.
4. Fremgangsmåde ifølge krav 1 og 2, kendetegnet ved, at referenceantistoffet og testantistoffet afviger især ved, at sidstnævnte blev fremstillet ved en fremgangsmåde, eller er blevet underkastet en behandling, som sigter mod at ændre niveauet for fucosylering af dettes Fc-fragment.
5. Fremgangsmåde til bestemmelse af niveauet for glycosylering af et antistof, omfattende følgende trin: - udførelse af fremgangsmåden ifølge krav 2, under anvendelse, i trin (ii), af adskillige konkurrerende antistoffer, som har kendte niveauer for glycosylering eller for deglycosylering, derefter - udøvelse af fremgangsmåden ifølge krav 2, under anvendelse, i trin (ii), af antistoffet, hvis niveau for glycosylering skal bestemmes, og - bestemmelse af niveauet for glycosylering af testantistoffet ved sammenligning af dettes EC50 med dette for de konkurrerende antistoffer, som har kendte niveauer for glycosylering eller for deglycosylering.
6. Fremgangsmåde til bestemmelse af niveauet for fucosylering for et antistof, omfattende følgende trin: - udførelse af fremgangsmåden ifølge krav 2, under anvendelse af, i trin (ii), adskillige konkurrerende antistoffer, som har kendte niveauer for fucosylering ellerfor defucosylering, efterfølgende, - udførelse af fremgangsmåden ifølge krav 4, under anvendelse af, i trin (ii), et antistof, hvis niveau for fucosylering eller for defucosylering skal bestemmes, og - bestemmelse af niveauet for fucosylering for testantistoffet ved sammenligning af dettes EC50 med dette for konkurrerende antistoffer, som har kendte niveauer for fucosylering ellerfor defucosylering.
7. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at Fc-receptoren er en gamma Fc-receptor.
8. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at Fc-receptoren er CD16a-receptoren eller en variant deraf.
9. Fremgangsmåde ifølge ethvert af kravene 1 til 8, kendetegnet ved, at suicid-enzymet vælges blandt: mutanterne af O6-alkylguanin-DNA-alkyltransferase, mutanterne af dehalogenase, eller et fragment af acylbærerproteinet.
10. Fremgangsmåde ifølge ethvert af de foregående krav, kendetegnet ved, at fremgangsmåden udøves med intakte celler.
11. Sæt af reagenser til udøvelse af fremgangsmåden ifølge ethvert af kravene 1 til 10, kendetegnet ved, at de omfatter en ekspressionsvektor, som omfatter DNA-sek-vensen, som koder for en Fc-receptor, og DNA-sekvensen, som koder for et suicid enzym, eller celler, som omfatter ekspressionsvektoren og i det mindste ét medlem af et par af FRET partnere.
12. Sæt af reagenser ifølge krav 11, kendetegnet ved, at suicid-enzymet vælges blandt mutanterne af dehalogenase, et fragment af acylbærerproteinet eller mutanterne af 06-alkylguanin-DNA-alkyltransferase.
13. Sæt at reagenser ifølge krav 11 eller 12, kendetegnet ved, at Fc-receptoren er CD16a-receptoren.
14. Sæt af reagenser ifølge ethvert af kravene 11 til 13, kendetegnet ved, at cellerne foreligger i frossen form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1158245A FR2980271B1 (fr) | 2011-09-16 | 2011-09-16 | Procede de determination de la glycosylation d'un anticorps |
PCT/FR2012/052049 WO2013038113A1 (fr) | 2011-09-16 | 2012-09-13 | Procede de determination de la glycosylation d'un anticorps |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2756305T3 true DK2756305T3 (da) | 2019-03-11 |
Family
ID=46968298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12767069.3T DK2756305T3 (da) | 2011-09-16 | 2012-09-13 | Fremgangsmåde til bestemmelse af glycosyleringen af et antistof |
Country Status (8)
Country | Link |
---|---|
US (1) | US9880176B2 (da) |
EP (1) | EP2756305B1 (da) |
JP (1) | JP6371703B2 (da) |
CN (1) | CN103959063B (da) |
DK (1) | DK2756305T3 (da) |
ES (1) | ES2711767T3 (da) |
FR (1) | FR2980271B1 (da) |
WO (1) | WO2013038113A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2926306C (en) * | 2013-11-05 | 2022-12-06 | F. Hoffmann-La Roche Ag | A method for determining the total amount and/or concentration of an analyte in a sample |
WO2016118084A1 (en) * | 2015-01-21 | 2016-07-28 | Agency For Science, Technology And Research | Immunoglobulin assays using nanoparticles |
JP6782716B2 (ja) * | 2015-06-25 | 2020-11-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗体またはリガンドの結合および機能を明らかにするための細胞ベースアッセイ法 |
CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
EP3356821B1 (en) * | 2015-10-02 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
FR3045053B1 (fr) * | 2015-12-09 | 2018-01-05 | Cisbio Bioassays | Agents complexants hydrosolubles a base de triazapyridinophane et complexes de lanthanide fluorescents correspondants |
WO2018114772A1 (en) * | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Assay for determining antibody or ligand binding and function |
PL3606946T3 (pl) | 2017-04-03 | 2022-11-28 | F. Hoffmann-La Roche Ag | Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15 |
BR112019019821A2 (pt) | 2017-04-05 | 2020-04-22 | Hoffmann La Roche | anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico |
JP7273858B2 (ja) * | 2018-06-15 | 2023-05-15 | シャンハイ ミラコーケン インコーポレイティド | 癌を治療するための方法と材料 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837169A (en) | 1981-07-01 | 1989-06-06 | Eastman Kodak Company | Polypyridine Fluorescent labels for immunoassay |
US4670572A (en) | 1981-07-01 | 1987-06-02 | Eastman Kodak Company | Phenolic fluorescent labels |
US4801722A (en) | 1981-07-01 | 1989-01-31 | Eastman Kodak Company | Coumarin chelates |
US4637988A (en) | 1981-07-01 | 1987-01-20 | Eastman Kodak Company | Fluorescent labels for immunoassay |
US4794191A (en) | 1981-07-01 | 1988-12-27 | Eastman Kodak Company | Fluorescent chelates |
US4859777A (en) | 1981-07-01 | 1989-08-22 | Eastman Kodak Company | Terpyridine chelating agents |
FR2570703B1 (fr) | 1984-09-26 | 1988-07-08 | Commissariat Energie Atomique | Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents |
US4761481A (en) | 1985-03-18 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Substituted pyridine derivatives |
US5106957A (en) | 1987-11-06 | 1992-04-21 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
US5116989A (en) | 1987-11-06 | 1992-05-26 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
US5032677A (en) | 1987-11-06 | 1991-07-16 | Baxter International Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
US5055578A (en) | 1987-11-06 | 1991-10-08 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
FR2624862B1 (fr) | 1987-12-18 | 1990-06-08 | Oris Ind | Cryptates de terres rares, procedes d'obtention, intermediaires de synthese et application a titre de marqueurs fluorescents |
SE8802575D0 (sv) | 1988-07-08 | 1988-07-08 | Wallac Oy | Terpyridine derivatives |
US5202423A (en) | 1988-07-08 | 1993-04-13 | Wallac Oy | Terpyridine derivatives |
FI88654C (fi) | 1991-03-15 | 1993-06-10 | Datacity Center Oy | Fluorescenshoejningsmetod |
FR2680787B1 (fr) | 1991-08-30 | 1994-11-04 | Cis Bio Int | Complexes macrocycliques de terres rares et leur utilisation pour reduire les interferences dans un dosage par fluorescence. |
US5622821A (en) | 1994-06-29 | 1997-04-22 | The Regents Of The University Of California | Luminescent lanthanide chelates and methods of use |
DE19806185C2 (de) * | 1998-02-02 | 1999-11-18 | Biogenes Gmbh | Immunoassay und Testkit zur Bestimmung von fucosyliertem Protein in einer biologischen Probe |
AU762754B2 (en) | 1999-02-18 | 2003-07-03 | Regents Of The University Of California, The | Salicylamide-lanthanide complexes for use as luminescent markers |
US6515113B2 (en) | 1999-02-18 | 2003-02-04 | The Regents Of The University Of California | Phthalamide lanthanide complexes for use as luminescent markers |
FR2810406B1 (fr) | 2000-06-15 | 2002-09-20 | Cis Bio Int | Nouveaux cryptates de terre rare peu sensibles a l'extinction de fluorescence |
US20030124621A1 (en) | 2000-07-04 | 2003-07-03 | Izumi Sugo | Method of assaying the function of fc fragment of antibody |
JP2003121445A (ja) * | 2001-10-09 | 2003-04-23 | Eisho Ryu | グリコシル化蛋白質の免疫分析方法およびその装置 |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
FR2844521B1 (fr) | 2002-09-13 | 2004-12-24 | Lab Francais Du Fractionnement | Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices |
JP2006501286A (ja) * | 2002-10-03 | 2006-01-12 | エコル・ポリテクニック・フェデラル・ドゥ・ローザンヌ(エーペーエフエル) | O6−アルキルグアニン−dnaアルキルトランスフェラーゼ |
EP1594962B1 (en) | 2003-01-31 | 2014-08-27 | Promega Corporation | Covalent tethering of functional groups to proteins |
EP1851547A2 (en) * | 2005-02-17 | 2007-11-07 | ChemCom S.A. | Novel in vitro methods for studying receptors recognizing volatile compounds |
ES2530265T3 (es) * | 2005-07-21 | 2015-02-27 | Genmab A/S | Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC |
FR2890174B1 (fr) * | 2005-08-30 | 2009-04-24 | Cis Bio Internat Sa | Procede pour la mise en evidence d'un processus biologique par mesure d'un fret |
FR2894983B1 (fr) | 2005-12-16 | 2012-08-17 | Lab Francais Du Fractionnement | Test de caracterisation des anticorps. |
BRPI0710011A2 (pt) * | 2006-04-14 | 2011-08-02 | Trubion Pharmaceuticals Inc | proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas |
EP1878747A1 (en) * | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
JP5352460B2 (ja) | 2006-08-15 | 2013-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ルミネッセント大環状ランタニド錯体 |
MX2009010120A (es) * | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
US20080248510A1 (en) * | 2007-04-03 | 2008-10-09 | Ulrich Brinkmann | HUMAN Fc GAMMA RECEPTOR III |
WO2008156083A1 (ja) * | 2007-06-18 | 2008-12-24 | Chugai Seiyaku Kabushiki Kaisha | 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法 |
GB2451106A (en) | 2007-07-18 | 2009-01-21 | Cis Bio Int | Lanthanide (III) ion complexing pyrazoyl-aza(thio)xanthone comprising compounds, their complexes and their use as fluorescent labels |
FR2934684B1 (fr) * | 2008-07-31 | 2012-11-16 | Cis Bio Int | Methode de detection de l'internalisation de proteines membranaires. |
FR2949156B1 (fr) * | 2009-08-13 | 2016-04-15 | Cis-Bio Int | Methode de determination de la liaison d'un compose donne a un recepteur membranaire |
-
2011
- 2011-09-16 FR FR1158245A patent/FR2980271B1/fr active Active
-
2012
- 2012-09-13 JP JP2014530296A patent/JP6371703B2/ja active Active
- 2012-09-13 DK DK12767069.3T patent/DK2756305T3/da active
- 2012-09-13 EP EP12767069.3A patent/EP2756305B1/fr active Active
- 2012-09-13 US US14/345,176 patent/US9880176B2/en active Active
- 2012-09-13 WO PCT/FR2012/052049 patent/WO2013038113A1/fr active Application Filing
- 2012-09-13 ES ES12767069T patent/ES2711767T3/es active Active
- 2012-09-13 CN CN201280056607.0A patent/CN103959063B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
FR2980271A1 (fr) | 2013-03-22 |
WO2013038113A1 (fr) | 2013-03-21 |
US20150024410A1 (en) | 2015-01-22 |
CN103959063A (zh) | 2014-07-30 |
EP2756305B1 (fr) | 2018-11-21 |
JP6371703B2 (ja) | 2018-08-08 |
JP2014527179A (ja) | 2014-10-09 |
FR2980271B1 (fr) | 2013-10-11 |
ES2711767T3 (es) | 2019-05-07 |
CN103959063B (zh) | 2016-11-09 |
EP2756305A1 (fr) | 2014-07-23 |
US9880176B2 (en) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2756305T3 (da) | Fremgangsmåde til bestemmelse af glycosyleringen af et antistof | |
CN108103098B (zh) | 一种化合物皮肤致敏体外评估细胞模型及其构建方法 | |
KR102606929B1 (ko) | 동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스 | |
Lisztwan et al. | Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45SKP2: evidence for evolutionary conservation in the subunit composition of the CDC34–SCF pathway | |
CN102649947A (zh) | 一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用 | |
CN110511286B (zh) | 一种rna碱基编辑分子 | |
PT2005185E (pt) | Métodos para a identificação de alvos polipeptídicos | |
CA2539439C (en) | Engineered zinc finger proteins for regulation of gene expression | |
US6642353B1 (en) | Peptide ligands for the erythropoietin receptor | |
TW200923366A (en) | Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics | |
JP2002335974A (ja) | 新規なメラノコルチン−4受容体の配列と動物の食欲及び代謝率を調節するのに有用な化合物を同定するためのスクリーニングアッセイ | |
KR102584628B1 (ko) | T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템 | |
JP2023025182A (ja) | T細胞レセプター及びt細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム | |
US20100055701A1 (en) | Fusion proteins for imaging the nucleus and chromosomes of live cells | |
CN116209674A (zh) | Krab融合阻遏物以及用于阻遏基因表达的方法和组合物 | |
KR20170131478A (ko) | 세포 표면 상에 펩타이드를 제시하기 위한 시스템 | |
CN107384917B (zh) | mini-gene剪接报告质粒及其构建方法与应用 | |
WO2000075184A1 (en) | Modulation of protein levels using the scf complex | |
US20030180801A1 (en) | Method for searching for gene encoding nuclear transport protein | |
CN110699380A (zh) | 一种ev71病毒核酸质粒及其构建方法及应用 | |
CN110922484B (zh) | 抗EGFRvIII抗体及其在疾病诊断或治疗中的应用 | |
CN100503832C (zh) | 关中奶山羊酪蛋白基因启动子表达载体 | |
CA2477002A1 (en) | Assays to monitor amyloid precursor protein processing | |
CN110628815B (zh) | 一种基于基因编辑技术的监测miRNA表达的报告基因探针及其构建方法 | |
US20030114644A1 (en) | Melanin concentrating hormone receptors |